Pomerantz LLP is investigating claims on behalf of investors in Emergent BioSolutions Inc. and Lincoln Educational Services Corp. over whether the companies and certain officers and/or directors engaged in securities fraud or other unlawful business practices. The Emergent inquiry follows its August 5, 2026, results for the quarter ended June 30, 2026, which included a $191.3 million non-cash impairment charge on its NARCAN asset group, a $180.2 million GAAP net loss, and an approximately 10.8% midpoint reduction to full-year revenue guidance. Emergent shares fell $2.23, or 29.58%, to close at $5.31 on August 6. The Lincoln inquiry follows its August 10, 2026, second-quarter results, which showed student starts rising approximately 1%; its shares fell $10.22, or 24.93%, to close at $30.77 that day.